Update for anyone on Levemir / NovoRapid – pen & insulin clarity
I wanted to share an update in case it helps others, as there’s a lot of confusing information going around.I’m currently on Levemir (basal) and NovoRapid (bolus) and, like many people, I was worried not just about changing insulin but about keeping everything on the same pen system.
Here’s what I’ve now confirmed:
- Levemir (insulin detemir) is being discontinued, with stock expected to last until end of 2026. There is now/was official clinical guidance (ABCD + PCDO Society, Aug 2025) telling clinicians to begin switching existing patients, not wait until the last minute.
- NovoRapid is NOT being discontinued as an insulin.
Only the FlexTouch disposable pen is being phased out. NovoRapid itself continues in Penfill cartridges and other formats. - Tresiba (insulin degludec) is a recommended replacement for Levemir and is fully available in Penfill cartridges.
Pen system – this was my main concern
If, like me, you want to keep one consistent pen type for safety and confidence:- Tresiba Penfill + NovoRapid Penfill both work in the same reusable NovoPen devices.
- NovoPen 6 can deliver up to 60 units in one injection (ideal for basal doses).
- NovoPen Echo / Echo Plus are capped at 30 units (fine for bolus if doses are smaller, but not for higher basal doses).
- one injection method
- one pen system
- no mixing of devices
- no last-minute panic about pens being withdrawn
- Basal: Tresiba Penfill (using NovoPen 6)
- Bolus: NovoRapid Penfill (same pen system)
If anyone else is in the middle of this and wants to compare notes or ask questions, feel free to reply. We shouldn’t be left anxious or guessing with something this important.
Document links I’ve found to help me.